In June 2016, pharmaceutical companies in Serbia belonging to the Association of Manufacturers of Innovative Drugs – INOVIA reported on transfers of value during 2015 to Serbian health-care professionals (HCPs) and health-care organisations (HCOs). The disclosure, without a precedent in the practice of the pharmaceutical companies with presence in Serbia, raises some interesting issues concerning […]